牛牛AI助理已提取核心訊息
Adial Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, initially filed on January 12, 2024. The company seeks to have the registration become effective on January 24, 2024, at 5:00 p.m. Eastern Time. This request was communicated through a letter to the SEC, confirming Adial Pharmaceuticals' understanding of its obligations under federal securities laws regarding the issuance of securities covered by the statement. The company has designated Leslie Marlow and Hank Gracin of Blank Rome LLP with the authority to modify or withdraw the acceleration request. The SEC has been asked to contact either Marlow or Gracin for any inquiries and to notify them once the acceleration has been granted. Cary Claiborne, the CEO of Adial Pharmaceuticals, signed the letter.
Adial Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, initially filed on January 12, 2024. The company seeks to have the registration become effective on January 24, 2024, at 5:00 p.m. Eastern Time. This request was communicated through a letter to the SEC, confirming Adial Pharmaceuticals' understanding of its obligations under federal securities laws regarding the issuance of securities covered by the statement. The company has designated Leslie Marlow and Hank Gracin of Blank Rome LLP with the authority to modify or withdraw the acceleration request. The SEC has been asked to contact either Marlow or Gracin for any inquiries and to notify them once the acceleration has been granted. Cary Claiborne, the CEO of Adial Pharmaceuticals, signed the letter.
Adial Pharmicals, Inc.已正式要求美國證券交易委員會（SEC）加快其最初於2024年1月12日提交的S-1表格註冊聲明的生效日期。該公司尋求使註冊於美國東部時間2024年1月24日下午5點生效。該請求是通過致美國證券交易委員會的一封信傳達的，證實了Adial Pharmaceals對聯邦證券法規定的與該聲明所涵蓋證券發行有關的義務的理解。該公司已指定Blank Rome LLP的萊斯利·馬洛和漢克·格拉辛有權修改或撤回加速請求。美國證券交易委員會被要求聯繫Marlow或Gracin進行任何查詢，並在加速批准後通知他們。Adial Pharmicals首席執行官卡里·克萊伯恩簽署了這封信。
Adial Pharmicals, Inc.已正式要求美國證券交易委員會（SEC）加快其最初於2024年1月12日提交的S-1表格註冊聲明的生效日期。該公司尋求使註冊於美國東部時間2024年1月24日下午5點生效。該請求是通過致美國證券交易委員會的一封信傳達的，證實了Adial Pharmaceals對聯邦證券法規定的與該聲明所涵蓋證券發行有關的義務的理解。該公司已指定Blank Rome LLP的萊斯利·馬洛和漢克·格拉辛有權修改或撤回加速請求。美國證券交易委員會被要求聯繫Marlow或Gracin進行任何查詢，並在加速批准後通知他們。Adial Pharmicals首席執行官卡里·克萊伯恩簽署了這封信。
有用
沒用
